
Cytophage Technologies Ltd. — Investor Relations & Filings
Cytophage Technologies Ltd. is a pioneering biotechnology company focused on developing synthetic bacteriophage products to prevent and treat bacterial infections, aiming to reduce and ultimately replace the use of conventional antibiotics. The company utilizes molecular genetic techniques and proprietary synthetic biology technology to create tailor-made, highly effective phages that are harmless to humans and animals. Cytophage's solutions address three primary markets: Animal Health (e.g., livestock illness prevention and growth enhancement), Food Safety (preventing disease spread without antibiotics), and Human Health (treating bacterial illnesses and hospital decontamination). A key competitive advantage is the rapid production timeline for targeted phages, enabling quick response to bacterial threats. The company is also engaged in advanced research, including the development of genetically engineered phage-based vaccines.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| News release - English.pdf | 2026-04-15 | English | |
| News release - English.pdf | 2026-04-15 | English | |
| News release - English.pdf | 2026-04-15 | English | |
| News release - English.pdf | 2026-04-15 | English | |
| Report of exempt distribution (45-106F1).pdf | 2025-12-08 | English | |
| News release - English.pdf | 2025-11-29 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
4 filings
| |||||
| 34546772 | News release - English.pdf | 2026-04-15 | English | ||
| 34543854 | News release - English.pdf | 2026-04-15 | English | ||
| 34538131 | News release - English.pdf | 2026-04-15 | English | ||
| 34534051 | News release - English.pdf | 2026-04-15 | English | ||
|
2025
11 filings
| |||||
| 32366236 | Report of exempt distribution (45-106F1).pdf | 2025-12-08 | English | ||
| 32363854 | News release - English.pdf | 2025-11-29 | English | ||
| 32352508 | News release - English.pdf | 2025-11-05 | English | ||
| 32344908 | News release - English.pdf | 2025-10-16 | English | ||
| 32315686 | Report of exempt distribution (45-106F1) (amended).pdf | 2025-09-15 | English | ||
| 32261461 | News release - English.pdf | 2025-07-28 | English | ||
| 13802110 | Report of exempt distribution (45-106F1).pdf | 2025-06-19 | English | ||
| 13800113 | News release - English.pdf | 2025-06-11 | French | ||
| 13796113 | News release - English.pdf | 2025-05-30 | English | ||
| 13796136 | Interim MD&A - English.pdf | 2025-05-30 | English | ||
| 13796135 | 52-109FV2 - Certification of interim filings - CFO (E).pdf | 2025-05-30 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
ACROBIOSYSTEMS CO.,LTD.
Provides recombinant proteins and reagents for life science…
|
301080 | CN | Professional, scientific and te… |
|
ACTINOGEN MEDICAL LIMITED
Developing cortisol-inhibiting therapies for Alzheimer's an…
|
ACW | AU | Professional, scientific and te… |
|
Active Biotech
Biotechnology company developing drugs for oncology and inf…
|
ACTI | SE | Professional, scientific and te… |
|
Adagene Inc.
Clinical-stage biotech developing antibody-based immunother…
|
ADAG | KY | Professional, scientific and te… |
|
ADALTA LIMITED
Clinical-stage biotech developing i-body protein therapeuti…
|
1AD | AU | Professional, scientific and te… |
|
Adaptive Biotechnologies Corp
Decodes the adaptive immune system to develop products for …
|
ADPT | US | Professional, scientific and te… |
|
Adeia Inc.
R&D company that licenses IP for the media, entertainment, …
|
ADEA | US | Professional, scientific and te… |
|
Aditxt, Inc.
Acquires, develops, and deploys health technologies to addr…
|
ADTX | US | Professional, scientific and te… |
|
Advanced Biomed Inc.
Develops microfluidic biochip diagnostic systems for precis…
|
ADVB | US | Professional, scientific and te… |
|
Advanced Proteome Therapeutics Corporation
Develops proprietary technology for chemical modification o…
|
APC.H | CA | Professional, scientific and te… |
Cytophage Technologies Ltd. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/48283/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=48283 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=48283 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=48283 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 48283}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Cytophage Technologies Ltd. (id: 48283)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.